Literature DB >> 21947086

Prevalence of C282Y, H63D, and S65C mutations in hereditary HFE-hemochromatosis gene in Lithuanian population.

Laimutis Kucinskas1, Simonas Juzenas, Jurgita Sventoraityte, Ruta Cedaviciute, Astra Vitkauskiene, Vytenis Kalibatas, Jurate Kondrackiene, Limas Kupcinskas.   

Abstract

HFE-hemochromatosis is a common autosomal recessive disease caused by HFE gene mutations and characterized as iron overload and failure of different organs. The aim of this study was to determine the prevalence of C282Y (c.845 G>A), H63D (c.187 C>G), and S65C (c.193A>T) alleles of HFE gene in the Lithuanian population. One thousand and eleven healthy blood donors of Lithuanian nationality were examined in four different ethnic Lithuanian regions to determine HFE gene alleles and genotype frequencies. The samples of DNA were analyzed for the presence of restriction fragment length polymorphism and validated by DNA sequencing. Among 1,011 blood donors tested, the frequency of C282Y, H63D, and S65C alleles were 2.6%, 15.9%, and 1.9%, respectively. One third of the tested subjects (n = 336) had at least one of the C282Y or H63D HFE gene mutations. The screening of Lithuanian blood donors has detected 13 (1.3%) subjects with a genotype C282Y/C282Y or C282Y/H63D responsible for the development of HFE-hemochromatosis. The prevalence of C282Y mutation was significantly higher among the inhabitants of Zemaitija (Somogitia) at the Baltic Sea area (5.9%) in comparison to the regions of continental part of Lithuania (2.4% in Dzukija, 2.3% in Aukstaitija, and 2% in Suvalkija, p < 0.05). These data support the hypothesis that the p.C282Y mutation originated from Scandinavia and spread with the Vikings along the Baltic Sea coast. The first epidemiological investigation of HFE gene mutations in ethnic Lithuanians showed that the frequencies of H63D, C282Y, and S65C of HFE gene alleles are similar to the other North-Eastern Europeans, especially in the Baltic region (Estonia, Latvia), Poland, and part of Russia (Moscow region).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947086     DOI: 10.1007/s00277-011-1338-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Association between inherited monogenic liver disorders and chronic hepatitis C.

Authors:  Linda Piekuse; Madara Kreile; Agnese Zarina; Zane Steinberga; Valentina Sondore; Jazeps Keiss; Baiba Lace; Astrida Krumina
Journal:  World J Hepatol       Date:  2014-02-27

2.  Cholesteryl ester transfer protein (CETP) I405V polymorphism and cardiovascular disease in eastern European Caucasians - a cross-sectional study.

Authors:  Jasmin Bustami; Anna Sukiasyan; Juozas Kupcinskas; Jurgita Skieceviciene; Leonid Iakoubov; Malgorzata Szwed; Christoph Kleinle; Ralf R Schumann; Monika Puzianowska-Kuznicka; Lutz Hamann
Journal:  BMC Geriatr       Date:  2016-07-20       Impact factor: 3.921

3.  Difficult diagnosis of cardiac haemochromatosis: a case report.

Authors:  Vaida Sudmantaitė; Jelena Čelutkienė; Sigita Glaveckaite; Rimgaudas Katkus
Journal:  Eur Heart J Case Rep       Date:  2020-02-13

4.  Less functional variants of TLR-1/-6/-10 genes are associated with age.

Authors:  Lutz Hamann; Juozas Kupcinskas; Luis C Berrocal Almanza; Berrocal Almanza; Jurgita Skieceviciene; Andre Franke; Ute Nöthlings; Ralf R Schumann
Journal:  Immun Ageing       Date:  2015-07-08       Impact factor: 6.400

5.  The evolutionary adaptation of the C282Y mutation to culture and climate during the European Neolithic.

Authors:  Kathleen M Heath; Jacob H Axton; John M McCullough; Nathan Harris
Journal:  Am J Phys Anthropol       Date:  2016-01-22       Impact factor: 2.868

6.  EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).

Authors:  Graça Porto; Pierre Brissot; Dorine W Swinkels; Heinz Zoller; Outi Kamarainen; Simon Patton; Isabel Alonso; Michael Morris; Steve Keeney
Journal:  Eur J Hum Genet       Date:  2015-07-08       Impact factor: 4.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.